Related references
Note: Only part of the references are listed.Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction-The EMMY trial
Norbert J. Tripolt et al.
AMERICAN HEART JOURNAL (2020)
Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction
Kim A. Connelly et al.
CARDIOVASCULAR DIABETOLOGY (2020)
Rifampicin activates AMPK and alleviates oxidative stress in the liver as mediated with Nrf2 signaling
Eun Hye Lee et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2020)
Empagliflozin attenuates ischemia and reperfusion injury through LKB1/AMPK signaling pathway
Qingguo Lu et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2020)
Fibroblast growth factor 19 alleviates palmitic acid-induced mitochondrial dysfunction and oxidative stress via the AMPK/PGC-1α pathway in skeletal muscle
Ai Guo et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2020)
Empagliflozin protects heart from inflammation and energy depletion via AMPK activation
Chintan N. Koyani et al.
PHARMACOLOGICAL RESEARCH (2020)
SGLT2 Inhibitors Play a Salutary Role in Heart Failure via Modulation of the Mitochondrial Function
Yasuhiro Maejima
FRONTIERS IN CARDIOVASCULAR MEDICINE (2020)
No direct effect of SGLT2 activity on glucagon secretion
Rune E. Kuhre et al.
DIABETOLOGIA (2019)
Metabolism of the failing heart and the impact of SGLT2 inhibitors
Alvaro Garcia-Ropero et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2019)
Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction
Salva R. Yurista et al.
EUROPEAN JOURNAL OF HEART FAILURE (2019)
Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics
Carlos G. Santos-Gallego et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
1,25-Dihydroxyvitamin D Decreases Tertiary Butyl-Hydrogen Peroxide-Induced Oxidative Stress and Increases AMPK/SIRT1 Activation in C2C12 Muscle Cells
Eugene Chang
MOLECULES (2019)
Empagliflozin, an SGLT2 Inhibitor, Reduced the Mortality Rate after Acute Myocardial Infarction with Modification of Cardiac Metabolomes and Antioxidants in Diabetic Rats
Hiroto Oshima et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Pre-revascularization coronary wedge pressure as marker of adverse long-term left ventricular remodelling in patients with acute ST-segment elevation myocardial infarction
Madalin Constantin Marc et al.
SCIENTIFIC REPORTS (2018)
Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission
Hao Zhou et al.
REDOX BIOLOGY (2018)
Dapagliflozin Attenuates Na+/H+ Exchanger-1 in Cardiofibroblasts via AMPK Activation
Yumei Ye et al.
CARDIOVASCULAR DRUGS AND THERAPY (2018)
Reappraisal of Ischemic Heart Disease: Fundamental Role of Coronary Microvascular Dysfunction in the Pathogenesis of Angina Pectoris
Juan-Carlos Kaski et al.
CIRCULATION (2018)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Empagliflozin Limits Myocardial Infarction in Vivo and Cell Death in Vitro: Role of STAT3, Mitochondria, and Redox Aspects
Ioanna Andreadou et al.
FRONTIERS IN PHYSIOLOGY (2017)
SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice
Liang Xu et al.
EBIOMEDICINE (2017)
AMP-Activated Protein Kinase An Ubiquitous Signaling Pathway With Key Roles in the Cardiovascular System
Ian P. Salt et al.
CIRCULATION RESEARCH (2017)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Pantelis A. Sarafidis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction
Carlo G. Tocchetti et al.
EUROPEAN JOURNAL OF HEART FAILURE (2014)
Physiological role of AMP-activated protein kinase in the heart: graded activation during exercise
DL Coven et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2003)
Share Paper
